LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | GW843682X | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1305 | 4223 | 0.3091 | -0.0341 |
| SK-BR-3 | HG-5-113-01 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1494 | 4223 | 0.3539 | 0.0329 |
| SK-BR-3 | HG-5-88-01 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 3503 | 4223 | 0.8296 | 0.7449 |
| SK-BR-3 | Imatinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 4581 | 4223 | 1.0848 | 1.1270 |
| SK-BR-3 | JNK-9L | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1952 | 4223 | 0.4624 | 0.1953 |
| SK-BR-3 | JW-7-24-1 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 2594 | 4223 | 0.6142 | 0.4226 |
| SK-BR-3 | Lapatinib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1574 | 4223 | 0.3728 | 0.0612 |
| SK-BR-3 | LDN-193189 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4146 | 4223 | 0.9818 | 0.9727 |
| SK-BR-3 | Linifanib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 4424 | 4223 | 1.0476 | 1.0712 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3545 | 4223 | 0.8396 | 0.7599 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1203 | 4223 | 0.2849 | -0.0702 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP6 | 72 | hr | 1401 | 1214 | 4223 | 0.2876 | -0.0662 |
| SK-BR-3 | MK2206 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 2472 | 4223 | 0.5854 | 0.3794 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1481 | 4223 | 0.3509 | 0.0284 |
| SK-BR-3 | Nilotinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4831 | 4223 | 1.1439 | 1.2155 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 3638 | 4223 | 0.8616 | 0.7929 |
| SK-BR-3 | NU7441 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3859 | 4223 | 0.9138 | 0.8710 |
| SK-BR-3 | Dactolisib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1349 | 4223 | 0.3196 | -0.0184 |
| SK-BR-3 | NVP-TAE684 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 3458 | 4223 | 0.8189 | 0.7290 |
| SK-BR-3 | Palbociclib | 1.11 | uM | LJP6 | 72 | hr | 1401 | 3028 | 4223 | 0.7170 | 0.5764 |
| SK-BR-3 | PD0325901 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 3426 | 4223 | 0.8113 | 0.7176 |
| SK-BR-3 | PD0325901 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 3240 | 4223 | 0.7672 | 0.6516 |
| SK-BR-3 | PD173074 | 1.11 | uM | LJP6 | 72 | hr | 1401 | 4453 | 4223 | 1.0544 | 1.0815 |
| SK-BR-3 | PD184352 | 1.11 | uM | LJP5 | 72 | hr | 1401 | 4402 | 4223 | 1.0425 | 1.0636 |
| SK-BR-3 | Pelitinib | 1.11 | uM | LJP5 | 72 | hr | 1401 | 1389 | 4223 | 0.3291 | -0.0042 |